World Health Organization, 2011. Monitoring and Epidemiological Assessment of Mass Drug Administration in the Global Programme to Eliminate Lymphatic Filariasis: A Manual for National Elimination Programmes. Geneva, Switzerland: WHO.
World Health Organization, 2015. Global programme to eliminate lymphatic filariasis: progress report, 2014. Wkly Epidemiol Rec 90: 489–504.
Hopkins DR et al.., 2002. Lymphatic filariasis elimination and schistosomiasis control in combination with onchocerciasis control in Nigeria. Am J Trop Med Hyg 67: 266–272.
Richards FO et al.., 2011. Epidemiological and entomological evaluations after six years or more of mass drug administration for lymphatic filariasis elimination in Nigeria. PLoS Negl Trop Dis 5: e1346.
King JD, Eigege A, Umaru J, Jip N, Miri E, Jiya J, Alphonsus KM, Sambo Y, Graves P, Richards F Jr, 2012. Evidence for stopping mass drug administration for lymphatic filariasis in some, but not all local government areas of Plateau and Nasarawa States, Nigeria. Am J Trop Med Hyg 87: 272–280.
Pacific Programme to Eliminate Lymphatic Filariasis (PacELF), 2004. PacMAN (PacELF Monitoring and Analysis Network) Book: Country-Specific Monitoring and Evaluation, and Mosquito Control Plans. Suva, Fiji: PacELF.
Michael E, Malecela-Lazaro MN, Simonsen PE, Pedersen EM, Barker G, Kumar A, Kazura JW, 2004. Mathematical modelling and the control of lymphatic filariasis. Lancet Infect Dis 4: 223–234.
Eigege A et al.., 2013. Long-lasting insecticidal nets are synergistic with mass drug administration for interruption of lymphatic filariasis transmission in Nigeria. PLoS Negl Trop Dis 7: e2508.
Evans DS et al.., 2014. Status of onchocerciasis transmission after more than a decade of mass drug administration for onchocerciasis and lymphatic filariasis elimination in central Nigeria: challenges in coordinating the stop MDA decision. PLoS Negl Trop Dis 8: e3113.
Wolstenholme AJ, Maclean MJ, Coates R, McCoy CJ, Reaves BJ, 2016. How do the macrocyclic lactones kill filarial nematode larvae? Invert Neurosci 16: 7.
World Health Organization, 2016. Guidelines for Stopping Mass Drug Administration and Verifying Elimination of Human Onchocerciasis: Criteria and Procedures. Geneva, Switzerland: WHO.
Chesnais C, Missamou F, Pion S, Bopda J, Louya F, Majewski A, Fischer P, Weil G, Boussinesq M, 2014. A case study of risk factors for lymphatic filariasis in the Republic of Congo. Parasit Vectors 7: 300.
Neglected Tropical Diseases Support Center, 2015. The Task Force for Global Health, Survey Sample Builder 2.3. Available at: http://www.ntdsupport.org/resources/transmission-assessment-survey-sample-builder. Accessed January 4, 2017.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||381||140||6|
Nigeria has the largest population at risk for lymphatic filariasis (LF) in Africa. This study used a transmission assessment survey (TAS) to determine whether mass drug administration (MDA) for LF could stop in 21 districts, divided into four evaluation units (EUs), of Plateau and Nasarawa States, Nigeria, after 8–12 years of annual albendazole–ivermectin treatment. A total of 7,131 first- and second-year primary school children (approximately 6–7 years old) were tested for LF antigen by immunochromatographic test (ICT) from May to June 2012. The target sample size of 1,692 was exceeded in each EU (range = 1,767–1,795). A total of 25 (0.4%) individuals were ICT positive, with the number of positives in each EU (range = 3–11) less than the TAS cutoff of 20, meaning that LF transmission had been reduced below sustainable levels. As a result, 3.5 million annual albendazole–ivermectin treatments were halted in 2013. Combined with the previous halt of MDA for LF in other parts of Plateau and Nasarawa, these are the first Nigerian states to stop LF MDA statewide. Posttreatment surveillance is ongoing to determine if LF transmission has been interrupted.
Authors’ addresses: Abel Eigege, John Umaru, Solomon E. Adelamo, Bulus Mancha, and Emmanuel S. Miri, The Carter Center, Jos, Plateau State, Nigeria, E-mails: firstname.lastname@example.org, email@example.com, firstname.lastname@example.org, email@example.com, and firstname.lastname@example.org. Darin S. Evans, United States Agency for International Development (USAID), Washington, DC, E-mail: email@example.com. Gregory S. Noland, Emily P. Griswold, and Frank O. Richards Jr., The Carter Center, Atlanta, GA, E-mails: firstname.lastname@example.org, email@example.com, and firstname.lastname@example.org. Emmanuel Davies and Bridget Okoeguale, Federal Ministry of Health, Abuja, Nigeria, E-mails: email@example.com and firstname.lastname@example.org. Jonathan D. King, Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland, E-mail: email@example.com.